Kuster, S. P. et al. Incidence of influenza in healthy adults and healthcare workers: a systematic review and meta-analysis. PLoS ONE 6, e26239 (2011).
European Centre for Disease Prevention and Control. Survey Report on National Seasonal Influenza Vaccination Recommendations and Coverage Rates in EU/EEA Countries: Data from the 2024 ECDC Influenza Survey, 2021–22 to 2023–24 Influenza Seasons (Publications Office, 2024).
McLean, H. Q. & Belongia, E. A. Influenza vaccine effectiveness: new insights and challenges. Cold Spring Harb. Perspect. Med. 11, a038315 (2021).
Gouma, S., Anderson, E. M. & Hensley, S. E. Challenges of making effective influenza vaccines. Annu. Rev. Virol. 7, 495–512 (2020).
Belongia, E. A. et al. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev. Vaccines 16, 1–14 (2017).
Skowronski, D. M. et al. Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during A(H3N2) epidemics in Canada, 2010–2011 to 2014–2015. J. Infect. Dis. 215, 1059–1099 (2017).
Jones-Gray, E., Robinson, E. J., Kucharski, A. J., Fox, A. & Sullivan, S. G. Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis. Lancet Respir. Med. 11, 27–44 (2023).
Beyer, W. E., de Bruijn, I. A., Palache, A. M., Westendorp, R. G. & Osterhaus, A. D. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch. Intern. Med. 159, 182–188 (1999).
Martínez-Baz, I. et al. Effect of repeated vaccination with the same vaccine component against 2009 pandemic influenza A(H1N1) virus. J. Infect. Dis. 215, 847–855 (2017).
Ramsay, L. C. et al. The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med. 17, 9 (2019).
McLean, H. Q. et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am. 59, 1375–1385 (2014).
Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg.70, 767 (1972).
Coudeville, L. et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med. Res. Methodol. 10, 18 (2010).
Yuan, H.-Y. et al. The impact of stratified immunity on the transmission dynamics of influenza. Epidemics 20, 84–93 (2017).
Ranjeva, S. et al. Age-specific differences in the dynamics of protective immunity to influenza. Nat. Commun. 10, 1660 (2019).
Lansbury, L. E. et al. Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis. Vaccine 35, 1996–2006 (2017).
Madhun, A. S. et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 29, 266–273 (2010).
Trieu, M.-C. et al. Antibody responses to influenza A/H1N1pdm09 virus after pandemic and seasonal influenza vaccination in healthcare workers: a 5-year follow-up study. Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am. 68, 382–392 (2019).
Hauser, M. I., Muscatello, D. J., Soh, A. C. Y., Dwyer, D. E. & Turner, R. M. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines. Vaccine 37, 4246–4255 (2019).
Gostic, K. M., Ambrose, M., Worobey, M. & Lloyd-Smith, J. O. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science 354, 722–726 (2016).
Gostic, K. M. et al. Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics. PLoS Pathog. 15, e1008109 (2019).
Gouma, S. et al. Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility. Nat. Commun. 11, 4566 (2020).
Budd, A. P. et al. Birth cohort effects in influenza surveillance data: evidence that first influenza infection affects later influenza-associated illness. J. Infect. Dis. 220, 820–829 (2019).
Wu, N. C. et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 13, e1006682 (2017).
Zost, S. J. et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl. Acad. Sci. USA114, 12578–12583 (2017).
Liu, F. et al. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination. J. Clin. Investig. 131, e146138 (2021).
Skowronski, D. M. et al. Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE 9, e92153 (2014).
Belongia, E. A. et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect. Dis. 16, 942–951 (2016).
Ananworanich, J. et al. Safety and immunogenicity of mRNA-1010, an investigational seasonal influenza vaccine, in healthy adults: final results from a phase 1/2 randomized trial. J. Infect. Dis. 231, e113–e122 (2025).
Rudman Spergel, A. K. et al. mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial. Nat. Med. 1–10 https://doi.org/10.1038/s41591-025-03591-0. (2025).
Fonville, J. M. et al. Antibody landscapes after influenza virus infection or vaccination. Science 346, 996–1000 (2014).
Ertesvåg, N. U. et al. Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses. NPJ Vaccines 7, 67 (2022).
Carlock, M. A., Allen, J. D., Hanley, H. B. & Ross, T. M. Longitudinal assessment of human antibody binding to hemagglutinin elicited by split-inactivated influenza vaccination over six consecutive seasons. PLoS ONE 19, e0301157 (2024).
Plant, E. P. et al. Different repeat annual influenza vaccinations improve the antibody response to drifted influenza strains. Sci. Rep. 7, 5258 (2017).
Sasaki, S. et al. Influence of Prior Influenza Vaccination on Antibody and B-Cell Responses. PLoS ONE 3, e2975 (2008).
de Bruijn, I. A. et al. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J. Infect. Dis. 179, 31–36 (1999).
Reber, A. J. et al. Preexisting immunity, more than aging, influences influenza vaccine responses. Open Forum Infect. Dis. 2, ofv052 (2015).
Feng, J. et al. Antibody quantity versus quality after influenza vaccination. Vaccine 27, 6358–6362 (2009).
Sherman, A. C. et al. The effects of imprinting and repeated seasonal influenza vaccination on adaptive immunity after influenza vaccination. Vaccines 8, 663 (2020).
Zelner, J., Petrie, J. G., Trangucci, R., Martin, E. T. & Monto, A. S. Effects of sequential influenza A(H1N1)pdm09 vaccination on antibody waning. J. Infect. Dis. 220, 12–19 (2019).
Strengell, M. et al. Antibody responses against influenza A(H1N1)pdm09 virus after sequential vaccination with pandemic and seasonal influenza vaccines in Finnish healthcare professionals. Influenza Other Respir. Viruses 7, 431–438 (2013).
Sanyal, M. et al. Diminished B-cell response after repeat influenza vaccination. J. Infect. Dis. 219, 1586–1595 (2019).
Andrews, S. F. et al. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response. J. Virol. 89, 3308–3317 (2015).
Tsang, J. S. et al. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell 157, 499–513 (2014).
Richards, K. A. et al. Evidence that blunted CD4 T-cell responses underlie deficient protective antibody responses to influenza vaccines in repeatedly vaccinated human subjects. J. Infect. Dis. 222, 273–277 (2020).
World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2025–2026 northern hemisphere influenza season. https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2025-2026-nh-influenza-season (2025).
Lartey, S. et al. Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Hum. Vaccines Immunother. 11, 1654–1662 (2015).
Smith, D. J., Forrest, S., Ackley, D. H. & Perelson, A. S. Variable efficacy of repeated annual influenza vaccination. Proc. Natl. Acad. Sci. USA96, 14001–14006 (1999).
Wedde, M., Biere, B., Wolff, T. & Schweiger, B. Evolution of the hemagglutinin expressed by human influenza A(H1N1)pdm09 and A(H3N2) viruses circulating between 2008–2009 and 2013–2014 in Germany. Int. J. Med. Microbiol. IJMM 305, 762–775 (2015).
Amdam, H. et al. Functional and binding H1N1pdm09-specific antibody responses in occasionally and repeatedly vaccinated healthcare workers: a five-year study (2009–2014). Front. Immunol. 12, 748281 (2021).
Madsen, A., Jul-Larsen, Å., Trieu, M.-C., Krammer, F. & Cox, R. J. Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: dissecting the HA specific antibody response. NPJ Vaccines 6, 45 (2021).
Eidem, S. et al. Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations. Vaccine 33, 4146–4154 (2015).
Frasca, D., Diaz, A., Romero, M. & Blomberg, B. B. The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations. Vaccine 34, 2834–2840 (2016).
Trieu, M.-C. et al. Long-term Maintenance of the Influenza-Specific Cross-Reactive Memory CD4+ T-Cell Responses Following Repeated Annual Influenza Vaccination. J. Infect. Dis. 215, 740–749 (2017).
Trieu, M.-C. et al. Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. NPJ Vaccines 3, 37 (2018).
Cowling, B. J. et al. Preliminary findings from the dynamics of the immune responses to repeat influenza vaccination exposures (DRIVE I) study: a randomized controlled trial. Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am. 79, 901–909 (2024).
Waldock, J. et al. Assay harmonization and use of biological standards to improve the reproducibility of the hemagglutination inhibition assay: a FLUCOP collaborative study. mSphere 6, e00567 (2021).
